PLEK

Across TCGA pan-cancer cohorts, PLEK Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PLEK data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher PLEK Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLEK expression acts as an unfavorable survival marker.

BRCA, DLBC, and LIHC are the cancer types where PLEK Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.118	0.527	<.001	28	view →
DLBC	OS	Median	II,III,IV	0.118	0.802	.025	12	view →
LIHC	OS	Median	All	0.025	0.775	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PLEK–BRCA (DFS)

Open the BRCA breakdown →